Furthermore, Falkevall et al. [62] utilized a vascular endothelial growth factor-B (VEGF-B) antagonist to inhibit the progression of white adipose tissue inflammation, revolved insulin resistance in white adipose tissue, and reduced hormone-sensitive adiponectin activity, resulting in improvement of NAFLD. The gene discussed is VEGFB; the disease is metabolic dysfunction-associated steatotic liver disease.